Brought to you by 
Medeva licenses US rights to Anthra's AD32
13 May 2013
Executive Summary
Medeva licensed exclusive US rights to Anthra's anthracycline derivative, AD32, which is being developed for bladder cancer. It will also acquire a 1% equity interest in Anthra, and US rights to all indications for AD32.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Medeva licenses US rights to Anthra's AD32
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice